Intratympanic steroid injection as a first-line therapy in uremia patients with sudden sensorineural hearing loss.

Conclusions: ITSI as a first-line therapy in uremia patients with SSNHL offers a valid and safe treatment compared with intravenous systemic steroid treatment. A specific pathophysiology caused by possible sodium pump paralysis may be explained for uremia patients with SSNHL.

Objective: To compare the efficacy of intratympanic steroid injection (ITSI) with that of systemic intravenous steroids as a first-line therapy in uremia patients with sudden sensorineural hearing loss (SSNHL).

Basal cell carcinoma of the external auditory canal.

Basal cell carcinomas of the EAC are known to be locally aggressive, although they are not associated with regional lymph node metastasis.